NCT06005974Phase 2Terminated

A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation

Study sponsor: Recursion Pharmaceuticals Inc. · RXRX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-02-24Actual
Enrollment · participants18Actual
Source updated2026-02-23Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 6 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: To evaluate the safety and tolerability of REC-4881 Measure: To evaluate the preliminary anti-tumor activity of REC-4881 as measured by Objective Response Rate (ORR). After: Measure: Number of Participants with Dose Limiting Toxicities Measure: Objective Response Rate.

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 60 participants (planned). After: 18 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Jan 2027. After: 24 Feb 2025.

Recruitment status changed

Before: Active not recruiting. After: Terminated.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview